U.S. Markets open in 3 hrs 39 mins

Catalyst Biosciences, Inc. (CBIO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.3602+0.0019 (+0.53%)
At close: 04:00PM EDT
0.3676 +0.01 (+2.05%)
After hours: 07:58PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3583
Bid0.0000 x 900
Ask0.0000 x 3200
Day's Range0.3570 - 0.3851
52 Week Range0.3500 - 5.2000
Avg. Volume334,846
Market Cap11.314M
Beta (5Y Monthly)1.95
PE Ratio (TTM)N/A
EPS (TTM)-3.0550
Earnings DateMar 02, 2022 - Mar 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateAug 20, 2015
1y Target Est11.67
  • GlobeNewswire

    Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results

    SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2022. “In the first quarter, we regained the rights to CB 2782-PEG, a C3 degrader protease, for the potential treatment of dry age-related macular degeneration (“AMD”) and now have full rights to two wholly-owned, potential best-in-class complement candidates that may provide compelling opportunities in o

  • Simply Wall St.

    Here's Why Catalyst Biosciences (NASDAQ:CBIO) Must Use Its Cash Wisely

    We can readily understand why investors are attracted to unprofitable companies. For example, although...

  • GlobeNewswire

    Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate Update

    SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update. “In late 2021 we announced a strategic change in corporate strategy, pivoting from hemophilia to a highly promising complement therapeutics and protease medicines platform,” said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. “T